Share on StockTwits

CombiMatrix (NASDAQ:CBMX) CEO Mark D. Mcdonough acquired 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 27th. The shares were purchased at an average price of $2.02 per share, with a total value of $24,240.00. Following the completion of the purchase, the chief executive officer now directly owns 13,500 shares in the company, valued at approximately $27,270. The purchase was disclosed in a document filed with the SEC, which is available at this link.

CombiMatrix (NASDAQ:CBMX) traded down 3.90% during mid-day trading on Thursday, hitting $1.97. 167,693 shares of the company’s stock traded hands. CombiMatrix has a 1-year low of $1.91 and a 1-year high of $4.44. The stock’s 50-day moving average is $2.16 and its 200-day moving average is $2.49. The company’s market cap is $21.8 million.

Separately, analysts at Zacks reiterated an “outperform” rating on shares of CombiMatrix in a research note on Friday, August 8th. They now have a $3.50 price target on the stock.

CombiMatrix Corporation is a molecular diagnostics company. The Company operates in the field of genetic analysis and molecular diagnostics through its wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc located in Irvine, California.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.